[Movember health care initiative 2019: prostate cancer screening at the University Hospital Frankfurt].
Urologische Prostatakrebsvorsorge im Rahmen der Movember-Gesundheitsinitiative 2019 am Universitätsklinikum Frankfurt.
Awareness campaign
Cancer check up
PSA screening
Preventive medicine
Prostata-specific antigen
Journal
Der Urologe. Ausg. A
ISSN: 1433-0563
Titre abrégé: Urologe A
Pays: Germany
ID NLM: 1304110
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
pubmed:
4
7
2020
medline:
11
11
2020
entrez:
4
7
2020
Statut:
ppublish
Résumé
Men die earlier than women in Germany. Men also have impaired access to cancer screening compared to women. Our Movember campaign 2019 at University Hospital Frankfurt (UKF) aimed at improving health care awareness in the context of prostate cancer checkup. In November 2019, every male employee of the UKF with a minimum age of 45 yrs (or 40 yrs with a first degree relative with prostate cancer) was offered a free prostate cancer checkup. This checkup contained digital rectal examination (DRE), transrectal ultrasound and PSA (prostata-specific antigen) testing. Overall, 121/840 employees (14.4%) participated in the Movember campaign. A first degree relative with prostate cancer was reported in overall by 14% of the participants (n = 17). At least one prior prostate cancer check up had 33%. A total of 2.5% (n = 3) had one prior negative prostate biopsy. Median age was 54 yrs (interquartile range 50-58). Median PSA level was 0.9 ng/ml and median free-PSA 0.3 ng/ml. A suspicious DRE was found in 5% (n = 6). After stratification according to age (≤ 50 yrs vs. > 50 yrs), participants over 50 yrs had a significantly higher PSA level (1.0 ng/ml vs. 0.7 ng/ml, p < 0.01) and had more frequently at least one prior prostate cancer checkup in the past (42.0 vs. 12.1%, p < 0.01). All suspicious DREs were in the cohort > 50 yrs. Overall, 32.2% (n = 39) had at least a suspicious checkup. A total of 3.3% (n = 4) had suspicious PSA levels. 17.4% (n = 21) of the participants had a suspicious PSA ratio (< 20%) only. During follow-up, 6 prostate biopsies were performed, with the detection of one case of intermediate-risk prostate cancer (Gleason 3 + 4, pT3a, pPn1, pNx, R0). Overall, 121 employees participated in our Movember Prostate cancer checkup campaign with measurement of the PSA level. Suspicious results were recorded in 32.2%. One employee was diagnosed and successfully treated with an intermediate-risk prostate cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Men die earlier than women in Germany. Men also have impaired access to cancer screening compared to women.
OBJECTIVES
OBJECTIVE
Our Movember campaign 2019 at University Hospital Frankfurt (UKF) aimed at improving health care awareness in the context of prostate cancer checkup.
MATERIALS AND METHODS
METHODS
In November 2019, every male employee of the UKF with a minimum age of 45 yrs (or 40 yrs with a first degree relative with prostate cancer) was offered a free prostate cancer checkup. This checkup contained digital rectal examination (DRE), transrectal ultrasound and PSA (prostata-specific antigen) testing.
RESULTS
RESULTS
Overall, 121/840 employees (14.4%) participated in the Movember campaign. A first degree relative with prostate cancer was reported in overall by 14% of the participants (n = 17). At least one prior prostate cancer check up had 33%. A total of 2.5% (n = 3) had one prior negative prostate biopsy. Median age was 54 yrs (interquartile range 50-58). Median PSA level was 0.9 ng/ml and median free-PSA 0.3 ng/ml. A suspicious DRE was found in 5% (n = 6). After stratification according to age (≤ 50 yrs vs. > 50 yrs), participants over 50 yrs had a significantly higher PSA level (1.0 ng/ml vs. 0.7 ng/ml, p < 0.01) and had more frequently at least one prior prostate cancer checkup in the past (42.0 vs. 12.1%, p < 0.01). All suspicious DREs were in the cohort > 50 yrs. Overall, 32.2% (n = 39) had at least a suspicious checkup. A total of 3.3% (n = 4) had suspicious PSA levels. 17.4% (n = 21) of the participants had a suspicious PSA ratio (< 20%) only. During follow-up, 6 prostate biopsies were performed, with the detection of one case of intermediate-risk prostate cancer (Gleason 3 + 4, pT3a, pPn1, pNx, R0).
CONCLUSION
CONCLUSIONS
Overall, 121 employees participated in our Movember Prostate cancer checkup campaign with measurement of the PSA level. Suspicious results were recorded in 32.2%. One employee was diagnosed and successfully treated with an intermediate-risk prostate cancer.
Identifiants
pubmed: 32617622
doi: 10.1007/s00120-020-01265-y
pii: 10.1007/s00120-020-01265-y
pmc: PMC7547026
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
1237-1245Références
Cancer. 2008 Nov 15;113(10):2695-703
pubmed: 18853417
Medicine (Baltimore). 2018 Mar;97(13):e0249
pubmed: 29595681
JAMA. 1998 May 20;279(19):1542-7
pubmed: 9605898
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Nat Genet. 2013 Apr;45(4):385-91, 391e1-2
pubmed: 23535732
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
Surg Endosc. 2020 Feb 3;:
pubmed: 32016518
Ir J Med Sci. 2020 Aug;189(3):811-815
pubmed: 31838732
Cancer. 2003 Mar 15;97(6):1528-40
pubmed: 12627518
BMC Cancer. 2018 Sep 10;18(1):881
pubmed: 30200904
Mhealth. 2016 Nov 7;2:
pubmed: 27840816
Eur Urol. 2016 Jan;69(1):41-9
pubmed: 26361169
Prev Med. 2005 Jun;40(6):628-35
pubmed: 15850858
BJU Int. 2006 Jul;98(1):50-3
pubmed: 16831142
Urol Int. 2020;104(3-4):230-238
pubmed: 31770767
Urologe A. 2019 May;58(5):486-493
pubmed: 30874831
J Health Commun. 2018;23(2):181-189
pubmed: 29313761
Eur Urol. 2011 Aug;60(2):320-9
pubmed: 21458913
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
J Urol. 1995 Sep;154(3):1090-5
pubmed: 7543605
J Urol. 2013 Apr;189(4):1470-4
pubmed: 23206422
Eur Urol Focus. 2019 Mar 21;:
pubmed: 30905598